In acute myeloid leukemia (AML), mutational activation of the receptor tyrosine kinase 
Flt3-dependent transformation by inactivating c-Cbl mutations in AML
Running
Introduction
Receptor tyrosine kinases (RTKs) bind extracellular growth factors and activate intracellular signaling networks. The magnitude and kinetics of RTK activation are tightly regulated, since they determine the quality and extent of the biological response. 1 Attenuation of RTK signaling occurs by endocytosis and subsequent protein degradation. [2] [3] [4] Cbl proteins have been shown to be central players in these processes. [5] [6] [7] The members of the Cbl family, c-Cbl, Cbl-b, and Cbl-3 contain an N-terminal phosphotyrosine binding (PTB) domain that allows direct interaction with activated RTKs, and a RING finger domain that classifies Cbl proteins as E3 ubiquitin ligases.
5,8-10
Ubiquitylation of RTKs is important for their internalization, endocytic sorting, and targeting for degradation. 2 In addition to their ubiquitin E3 ligase activity, Cbl proteins also associate with the endocytic machinery via their C-terminus by recruiting proteins like CIN85 and endophilins. 11, 12 However, Cbl proteins are not only important for RTK signal termination, but also mediate positive RTK signaling events to downstream effectors. Upon phosphorylation, Cbl molecules bind signaling molecules including SHP-2, Gab2 and PI3-kinase. 13 In animal models, but not in human cancers, oncogenic forms of Cbl have been described that are characterized by loss of the E3 ubiquitin ligase activity. 14, 15 It has been reported that these oncogenic mutants of Cbl interact with activated RTKs and function in a dominant negative fashion. 16, 17 Aberrant signaling by the type III RTK Flt3 is an important event in the pathogenesis of AML. Flt3 strongly influences hematopoietic progenitor cell homeostasis and is highly expressed in AML. [18] [19] [20] [21] Also, about one third of AML cases harbour somatic, activating
Flt3 mutations that cause myeloid transformation. [21] [22] [23] [24] In contrast to activating mutations, For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From little is known about the potential functions of Flt3 in AML cases lacking Flt3 mutations.
Also, the mechanisms of Flt3 signal regulation and the role of Cbl proteins in these processes remain undetermined, although it has been shown that Flt3 activation is followed by Cbl phosphorylation. 25 Here, we analyzed the role of c-Cbl in the internalization, ubiquitylation and biological functions of wild-type Flt3 (Flt3-WT) and the most commonly described Flt3 mutations in AML, internal tandem duplication (Flt3-ITD). We found that the inhibition of Cbl function severely disturbed Flt3 signal transduction kinetics by blocking Flt3 internalization and ubiquitylation. As a consequence, interference with Cbl function induced ligandindependent, autoactive biological effects of Flt3. Also, we describe a novel E3-ligase inactivating c-Cbl mutation isolated from the blasts of one AML patient. This mutant Cbl protein interfered with the function of endogenous c-Cbl and displayed in vitro transforming activity in myeloid cells that was dependent on the presence of Flt3. To our knowledge, this represents the first case of a transforming Cbl mutation in a human cancer specimen, pointing towards a novel mechanism of disturbed RTK signal termination in human cancers that could be amenable to pharmacological kinase inhibition.
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From and anti-phospho-STAT5a/b were purchased from Upstate Biotechnology (Lake Placid, NY). The mouse monoclonal anti-actin antibody was purchased from Sigma (Taufkirchen, Germany). Purified anti-human-Flt3 antibody (clone SF1.340) was purchased from Beckman Coulter (Fullerton, CA). Phycoerythrin (PE)-labeled monoclonal mouse anti-human Flt3 antibodies as well as appropriate isotype controls were obtained from PharMingen (San Diego, CA). The Flt3-specific inhibitor SU11248 was a kind gift from Sugen (San Francisco, CA). Cycloheximide was purchased from Sigma (Taufkirchen, Germany).
Materials and methods

Reagents and antibodies
Recombinant human
Cell lines
The IL-3 dependent murine myeloid cell line 32Dcl3 (subsequently referred to as 32D) was kindly provided by Dr. Felicitas Rosenthal (Freiburg, Germany) and was cultured as described.
23,26 COS-7 and 293T cells were cultured in Dulbecco's modified Eagle's
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From medium (Invitrogen GmbH, Karlsruhe, Germany). Cells were maintained in a humidified incubator at 37°C and 5% CO 2 .
Generation of stable cell lines
The generation of 32D cells stably expressing wild-type Flt3 or Flt3-ITD has been previously described. 23, 24 For generating Cbl overexpressing 32D cell lines, parental 32D or 32D cells stably expressing Flt3 receptors were electroporated with different Cbl constructs (c-Cbl-WT, Cbl-70Z, Cbl-R420Q), as described. 23 The stable Cbl expressing bulk cultures were selected using neomycin (800 µg/mL). To avoid possible clonal selection, for each cell line, at least two bulk cultures were generated. All cell lines were generated and maintained in medium supplemented with WEHI conditioned medium as source of IL-3 until being used for the experiments.
Transient transfections
For transient expression experiments, COS-7 cells were transfected using SuperFect TM (QIAGEN, Hilden, Germany) according to the manufacturer's protocol. At 48 hours post transfection, cells were lysed and analyzed for expression of indicated proteins.
Patient samples
The patient samples were collected from patients enrolled in a treatment optimization trial in Germany. 27 Control total bone marrow samples were obtained from healthy donors. Written informed consent was obtained from all individuals. The use of human material for scientific purposes was approved by the ethics committee of each participating institution. After washing the membrane three times with TBS-T buffer, the GST fusion proteins were detected by western blotting using anti-GST antibodies (Santa Cruz, CA).
Flt3 protein half-life degradation analyses
32D cells expressing the indicated Flt3 proteins were cytokine deprived overnight in medium containing 0.5% FCS. Subsequently, cells were then exposed to 50 µg/mL of Cycloheximide for 2 hours at 37°C. Cells were then incubated with 100 ng/mL FL at 37°C. The experiment was stopped by cell lysis at the indicated time points. For densitometry, blots were scanned and the bands were quantified using the GelPro Analyser software (INTAS, Göttingen, Germany) according to the manufacturer's instructions. 
Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuickChange 
Results
Cbl associates with and is phosphorylated by Flt3
In order to analyze the effects of Cbl on Flt3 signal mitigation, we generated 32D cell lines that stably overexpressed Flt3 together with c-Cbl or a published dominant negative version of c-Cbl, Cbl-70Z. 15 ,28 First, we analyzed whether ligand-induced Flt3 activation led to enhanced phosphorylation of c-Cbl. As shown in Figure 1A 
Cbl-70Z induces ligand-independent growth in cooperation with Flt3
Having observed critical importance of Cbl proteins for Flt3 ubiquitylation, we examined Cultures expressing only Cbl-70Z (without Flt3 receptors) survived longer after cytokine withdrawal ( Figure 3B ). However, these cultures failed to proliferate in a cytokine
and died off after a few days of culture in cytokine free media ( Figure 3A) . These findings suggest that Cbl-70Z conferred apoptosis resistance to these cells but was incapable of inducing significant proliferative activity. Interestingly, coexpression of Flt3-WT and Cbl-70Z rescued proliferation and these cells were able to grow cytokine independently for extended time periods. In contrast, expression of Flt3-WT (in the absence of FL) alone did not lead to proliferation. Finally, we analyzed the effects of Cbl-70Z on cytokine-independent and Flt3-dependent proliferation by directly comparing it with IL-3-dependent proliferation in thymidine incorporation assays ( Figure   3C ). In the absence of Flt3, Cbl-70Z induced only minimal proliferation ( Figure 3C ).
Coexpression of Cbl-70Z with Flt3-WT induced a robust proliferative response that was further enhanced by Flt3 activation. Importantly, a Flt3-specific inhibitor, SU11248, suppressed proliferation in a dose-dependent manner. Notably, the major effects of Cbl-70Z were again independent from the presence of FL, although they required the presence of the receptor. In contrast to wild-type Flt3, we did not observe any significant synergistic effects of the coexpression of Flt3-ITD with Cbl-70Z, presumably due to full activation of proliferative signals by the constitutively active Flt3-ITD alone (data not shown).
Identification and characterization of a novel Cbl point mutation in AML
The data presented above suggested that interference with Cbl function may be involved in myeloid transformation. In animal models, several oncogenic Cbl mutations have been described, and all are clustered in the RING domain or in the linker region. Figure 4A ). The presence of the mutation was independently verified in the cDNA and the genomic DNA in both directions, using different PCR products and different sequencing primers. Arginine 420 is evolutionary highly conserved and has been suggested to be involved in the contact site of Cbl with the E2 ubiquitin-conjugation enzyme UbcH7. 31 We cloned this c-Cbl mutant (Cbl-R420Q) into an expression vector and analyzed its association with Flt3 and the consequences of its presence for Flt3 ubiquitylation and internalization. As shown in Figure 4B , Cbl-R420Q associates with Flt3-WT. Flt3 was readily ubiquitylated after ligand-activation in the presence of wild-type c-Cbl, but not in the presence of Cbl-R420Q ( Figure 4B and C) . In vitro ubiquitylation assays revealed that in contrast to the wild-type RING domain, the RING domain containing the R420Q mutation was unable to function as an E3 ubiquitin ligase for Flt3 ( Figure 4D ).
RTK signal mitigation has been shown to be dependent on Cbl mediated receptor internalization and ubiquitylation. 5,7,31,32 Therefore, we analyzed the consequences of Cbl-R420Q overexpression for RTK internalization. Interestingly, Cbl-R420Q strongly inhibited ligand-induced internalization of EGFR and PDGFR, a process dependent on intact Cbl function ( Figure 4E ). Furthermore, Cbl-R420Q inhibited Flt3 internalization to a similar extent as Cbl-70Z.
In conclusion, we have identified a Cbl mutation in primary blasts from an AML patient that effectively inhibits ubiquitylation and internalization of RTKs upon overexpression.
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Cbl-R420Q has transforming capacity in the presence of Flt3
We next analyzed the biological significance of the AML-associated Cbl mutation (Cbl- 
31
. Indeed, we present biochemical evidence that the R420Q mutation To our knowledge the novel Cbl-R420Q mutation identified here is the first reported Cbl mutation with obvious transforming ability in human disease. Although we identified this mutation in a single patient, it is possible that alterations in the negative regulatory machinery of RTKs are more frequently involved in leukemogenic signal transduction.
First, Cbl proteins consist of a family of several members with presumably redundant
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From function. Dominant negative mutations in any Cbl family member may induce similar effects as observed for Cbl-R420Q. Also, termination of RTK signaling is a complex multi-step process, which requires several sorting, segregation, and degradation steps, each of which involve many different proteins. [43] [44] [45] It may well be that other proteins involved in these processes may be mutated more frequently in AML and possibly in other human cancers. This notion, at least in part, is also supported by data showing that proteins involved in the endocytosis machinery are often constituents of oncogenic fusion proteins. 39, 46, 47 Furthermore, inappropriate expression of proteins involved in endocytic sorting (i.e. Hrs and Tsg101) have also been implicated in human cancers. 39 The potent effects of the point mutation of c-Cbl on myeloid cell proliferation and survival warrants further search for such mutations in clonal myeloid disorders, especially in patients without known activating mutations in signaling intermediates.
Originally, c-Cbl was described as a proto-oncogene of an animal virus that induced lymphoma in mice. 48 It has been shown that the corresponding viral oncogene, v-Cbl, is a relatively weak oncogene. However, it is not quite clear, whether Cbl-mediated transformation is solely due to dominant-negative effects of oncogenic Cbl proteins, or whether the mutations also
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From provide a gain of function. Homozygous c-Cbl knockout mice do not display an obvious tumor phenotype, 5, 49 suggesting that the c-Cbl mutations that we analyzed here are not only dominant-negative over c-Cbl. One explanation could be that they are dominant negative over several Cbl family members, circumventing redundancy that could explain the lack of the knockout phenotype.
Alternatively, the transforming phenotype of oncogenic Cbl mutants could be due to an additional gain of function, which provides activating signals to the cells. For example, it has been shown that c-Cbl binds to and activates Cool-1, which on the one hand inhibits
Cbl-mediated receptor endocytosis and degradation, and on the other hand functions as a regulated guanine nucleotide exchange factor (GEF) for Cdc42. This (presumably proto-oncogenic) GEF activity is activated by its phosphorylation in Cbl-Cool-1-tyrosine kinase complexes. 50, 51 Furthermore, phosphorylated c-Cbl forms complexes with PI3-K leading to Akt and Erk activation. 52 The Src family kinases Fyn and Lyn associate more strongly with increasingly phosphorylated c-Cbl. [53] [54] [55] Recruitment of the CrkL adaptor protein by c-Cbl has been reported to facilitate activation of Jnk and Rap1. All these examples illustrate the extensive positive involvement of Cbl proteins in signaling. [56] [57] [58] Most of these activities have been mapped to the C-terminal multi-adaptor domain, which contains phosphotyrosine sites that can bind to positive signal regulators like SHP2 and PI3-K. 13, 52, 56, 59 Consequently, oncogenic Cbl proteins that retain the Cterminal part have been shown to be more potent than Cbl oncogenes lacking this domain. 5, 15 Furthermore, the phosphotyrosine sites in the C-terminus are highly phosphorylated in Cbl-70Z, suggesting that this region of Cbl may play an important role in oncogenic properties at least of Cbl-70Z. Interestingly, the novel Cbl-R420Q mutation fulfils all the requirements of potent Cbl oncogenes, since it only consists of a point Cbl proteins change the kinetics of Flt3-induced Erk activity. Cells were treated as described in (D) with the exception that they were exposed to FL for the indicated time
